Global Nuclear Medicine Imaging Agents Market Outlook and Growth Opportunities 2025

Summary

According to APO Research, the global Nuclear Medicine Imaging Agents market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Nuclear Medicine Imaging Agents is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Nuclear Medicine Imaging Agents is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Nuclear Medicine Imaging Agents market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Nuclear Medicine Imaging Agents is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Nuclear Medicine Imaging Agents market include Jubilant Pharma Limited, Foshan Rui Diao Pharmaceutical, Yantai Dongcheng, Navidea, Mallinckrodt, Lantheus, Guerbet, GE HealthCare and Eli Lilly and Company, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Nuclear Medicine Imaging Agents, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Nuclear Medicine Imaging Agents, also provides the sales of main regions and countries. Of the upcoming market potential for Nuclear Medicine Imaging Agents, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nuclear Medicine Imaging Agents sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Nuclear Medicine Imaging Agents market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Nuclear Medicine Imaging Agents sales, projected growth trends, production technology, application and end-user industry.

Nuclear Medicine Imaging Agents Segment by Company

Jubilant Pharma Limited
Foshan Rui Diao Pharmaceutical
Yantai Dongcheng
Navidea
Mallinckrodt
Lantheus
Guerbet
GE HealthCare
Eli Lilly and Company
Cardinal Health
Bracco Diagnostic
Blue Earth Diagnostics
Bayer AG
Abx Advanced Biochemical
Nuclear Medicine Imaging Agents Segment by Type

Nitrogen 13 Labeling
Technetium 99 Labeling
Fluorine 18 Labeling
Carbon 11 Labeling
Oxygen 15 Labeling
Others
Nuclear Medicine Imaging Agents Segment by Application

Clinical Stage
Early Diagnosis
Treatment Evaluation
Nuclear Medicine Imaging Agents Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Nuclear Medicine Imaging Agents status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Nuclear Medicine Imaging Agents market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Nuclear Medicine Imaging Agents significant trends, drivers, influence factors in global and regions.
6. To analyze Nuclear Medicine Imaging Agents competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine Imaging Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine Imaging Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine Imaging Agents.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nuclear Medicine Imaging Agents market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nuclear Medicine Imaging Agents industry.
Chapter 3: Detailed analysis of Nuclear Medicine Imaging Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Nuclear Medicine Imaging Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Nuclear Medicine Imaging Agents in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Nuclear Medicine Imaging Agents Sales Value (2020-2031)
1.2.2 Global Nuclear Medicine Imaging Agents Sales Volume (2020-2031)
1.2.3 Global Nuclear Medicine Imaging Agents Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Nuclear Medicine Imaging Agents Market Dynamics
2.1 Nuclear Medicine Imaging Agents Industry Trends
2.2 Nuclear Medicine Imaging Agents Industry Drivers
2.3 Nuclear Medicine Imaging Agents Industry Opportunities and Challenges
2.4 Nuclear Medicine Imaging Agents Industry Restraints
3 Nuclear Medicine Imaging Agents Market by Company
3.1 Global Nuclear Medicine Imaging Agents Company Revenue Ranking in 2024
3.2 Global Nuclear Medicine Imaging Agents Revenue by Company (2020-2025)
3.3 Global Nuclear Medicine Imaging Agents Sales Volume by Company (2020-2025)
3.4 Global Nuclear Medicine Imaging Agents Average Price by Company (2020-2025)
3.5 Global Nuclear Medicine Imaging Agents Company Ranking (2023-2025)
3.6 Global Nuclear Medicine Imaging Agents Company Manufacturing Base and Headquarters
3.7 Global Nuclear Medicine Imaging Agents Company Product Type and Application
3.8 Global Nuclear Medicine Imaging Agents Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Nuclear Medicine Imaging Agents Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Nuclear Medicine Imaging Agents Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Nuclear Medicine Imaging Agents Market by Type
4.1 Nuclear Medicine Imaging Agents Type Introduction
4.1.1 Nitrogen 13 Labeling
4.1.2 Technetium 99 Labeling
4.1.3 Fluorine 18 Labeling
4.1.4 Carbon 11 Labeling
4.1.5 Oxygen 15 Labeling
4.1.6 Others
4.2 Global Nuclear Medicine Imaging Agents Sales Volume by Type
4.2.1 Global Nuclear Medicine Imaging Agents Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Nuclear Medicine Imaging Agents Sales Volume by Type (2020-2031)
4.2.3 Global Nuclear Medicine Imaging Agents Sales Volume Share by Type (2020-2031)
4.3 Global Nuclear Medicine Imaging Agents Sales Value by Type
4.3.1 Global Nuclear Medicine Imaging Agents Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Nuclear Medicine Imaging Agents Sales Value by Type (2020-2031)
4.3.3 Global Nuclear Medicine Imaging Agents Sales Value Share by Type (2020-2031)
5 Nuclear Medicine Imaging Agents Market by Application
5.1 Nuclear Medicine Imaging Agents Application Introduction
5.1.1 Clinical Stage
5.1.2 Early Diagnosis
5.1.3 Treatment Evaluation
5.2 Global Nuclear Medicine Imaging Agents Sales Volume by Application
5.2.1 Global Nuclear Medicine Imaging Agents Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Nuclear Medicine Imaging Agents Sales Volume by Application (2020-2031)
5.2.3 Global Nuclear Medicine Imaging Agents Sales Volume Share by Application (2020-2031)
5.3 Global Nuclear Medicine Imaging Agents Sales Value by Application
5.3.1 Global Nuclear Medicine Imaging Agents Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Nuclear Medicine Imaging Agents Sales Value by Application (2020-2031)
5.3.3 Global Nuclear Medicine Imaging Agents Sales Value Share by Application (2020-2031)
6 Nuclear Medicine Imaging Agents Regional Sales and Value Analysis
6.1 Global Nuclear Medicine Imaging Agents Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Nuclear Medicine Imaging Agents Sales by Region (2020-2031)
6.2.1 Global Nuclear Medicine Imaging Agents Sales by Region: 2020-2025
6.2.2 Global Nuclear Medicine Imaging Agents Sales by Region (2026-2031)
6.3 Global Nuclear Medicine Imaging Agents Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Nuclear Medicine Imaging Agents Sales Value by Region (2020-2031)
6.4.1 Global Nuclear Medicine Imaging Agents Sales Value by Region: 2020-2025
6.4.2 Global Nuclear Medicine Imaging Agents Sales Value by Region (2026-2031)
6.5 Global Nuclear Medicine Imaging Agents Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Nuclear Medicine Imaging Agents Sales Value (2020-2031)
6.6.2 North America Nuclear Medicine Imaging Agents Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Nuclear Medicine Imaging Agents Sales Value (2020-2031)
6.7.2 Europe Nuclear Medicine Imaging Agents Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Nuclear Medicine Imaging Agents Sales Value (2020-2031)
6.8.2 Asia-Pacific Nuclear Medicine Imaging Agents Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Nuclear Medicine Imaging Agents Sales Value (2020-2031)
6.9.2 South America Nuclear Medicine Imaging Agents Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Nuclear Medicine Imaging Agents Sales Value (2020-2031)
6.10.2 Middle East & Africa Nuclear Medicine Imaging Agents Sales Value Share by Country, 2024 VS 2031
7 Nuclear Medicine Imaging Agents Country-level Sales and Value Analysis
7.1 Global Nuclear Medicine Imaging Agents Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Nuclear Medicine Imaging Agents Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Nuclear Medicine Imaging Agents Sales by Country (2020-2031)
7.3.1 Global Nuclear Medicine Imaging Agents Sales by Country (2020-2025)
7.3.2 Global Nuclear Medicine Imaging Agents Sales by Country (2026-2031)
7.4 Global Nuclear Medicine Imaging Agents Sales Value by Country (2020-2031)
7.4.1 Global Nuclear Medicine Imaging Agents Sales Value by Country (2020-2025)
7.4.2 Global Nuclear Medicine Imaging Agents Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.5.2 USA Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.6.2 Canada Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.8.2 Germany Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.9.2 France Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.9.3 France Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.11.2 Italy Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.12.2 Spain Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.13.2 Russia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.16.2 China Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.16.3 China Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.17.2 Japan Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.19.2 India Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.19.3 India Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.20.2 Australia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.24.2 Chile Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.26.2 Peru Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.28.2 Israel Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.29.2 UAE Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.31.2 Iran Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Nuclear Medicine Imaging Agents Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Nuclear Medicine Imaging Agents Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Nuclear Medicine Imaging Agents Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Jubilant Pharma Limited
8.1.1 Jubilant Pharma Limited Comapny Information
8.1.2 Jubilant Pharma Limited Business Overview
8.1.3 Jubilant Pharma Limited Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.1.4 Jubilant Pharma Limited Nuclear Medicine Imaging Agents Product Portfolio
8.1.5 Jubilant Pharma Limited Recent Developments
8.2 Foshan Rui Diao Pharmaceutical
8.2.1 Foshan Rui Diao Pharmaceutical Comapny Information
8.2.2 Foshan Rui Diao Pharmaceutical Business Overview
8.2.3 Foshan Rui Diao Pharmaceutical Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.2.4 Foshan Rui Diao Pharmaceutical Nuclear Medicine Imaging Agents Product Portfolio
8.2.5 Foshan Rui Diao Pharmaceutical Recent Developments
8.3 Yantai Dongcheng
8.3.1 Yantai Dongcheng Comapny Information
8.3.2 Yantai Dongcheng Business Overview
8.3.3 Yantai Dongcheng Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.3.4 Yantai Dongcheng Nuclear Medicine Imaging Agents Product Portfolio
8.3.5 Yantai Dongcheng Recent Developments
8.4 Navidea
8.4.1 Navidea Comapny Information
8.4.2 Navidea Business Overview
8.4.3 Navidea Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.4.4 Navidea Nuclear Medicine Imaging Agents Product Portfolio
8.4.5 Navidea Recent Developments
8.5 Mallinckrodt
8.5.1 Mallinckrodt Comapny Information
8.5.2 Mallinckrodt Business Overview
8.5.3 Mallinckrodt Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.5.4 Mallinckrodt Nuclear Medicine Imaging Agents Product Portfolio
8.5.5 Mallinckrodt Recent Developments
8.6 Lantheus
8.6.1 Lantheus Comapny Information
8.6.2 Lantheus Business Overview
8.6.3 Lantheus Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.6.4 Lantheus Nuclear Medicine Imaging Agents Product Portfolio
8.6.5 Lantheus Recent Developments
8.7 Guerbet
8.7.1 Guerbet Comapny Information
8.7.2 Guerbet Business Overview
8.7.3 Guerbet Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.7.4 Guerbet Nuclear Medicine Imaging Agents Product Portfolio
8.7.5 Guerbet Recent Developments
8.8 GE HealthCare
8.8.1 GE HealthCare Comapny Information
8.8.2 GE HealthCare Business Overview
8.8.3 GE HealthCare Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.8.4 GE HealthCare Nuclear Medicine Imaging Agents Product Portfolio
8.8.5 GE HealthCare Recent Developments
8.9 Eli Lilly and Company
8.9.1 Eli Lilly and Company Comapny Information
8.9.2 Eli Lilly and Company Business Overview
8.9.3 Eli Lilly and Company Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.9.4 Eli Lilly and Company Nuclear Medicine Imaging Agents Product Portfolio
8.9.5 Eli Lilly and Company Recent Developments
8.10 Cardinal Health
8.10.1 Cardinal Health Comapny Information
8.10.2 Cardinal Health Business Overview
8.10.3 Cardinal Health Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.10.4 Cardinal Health Nuclear Medicine Imaging Agents Product Portfolio
8.10.5 Cardinal Health Recent Developments
8.11 Bracco Diagnostic
8.11.1 Bracco Diagnostic Comapny Information
8.11.2 Bracco Diagnostic Business Overview
8.11.3 Bracco Diagnostic Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.11.4 Bracco Diagnostic Nuclear Medicine Imaging Agents Product Portfolio
8.11.5 Bracco Diagnostic Recent Developments
8.12 Blue Earth Diagnostics
8.12.1 Blue Earth Diagnostics Comapny Information
8.12.2 Blue Earth Diagnostics Business Overview
8.12.3 Blue Earth Diagnostics Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.12.4 Blue Earth Diagnostics Nuclear Medicine Imaging Agents Product Portfolio
8.12.5 Blue Earth Diagnostics Recent Developments
8.13 Bayer AG
8.13.1 Bayer AG Comapny Information
8.13.2 Bayer AG Business Overview
8.13.3 Bayer AG Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.13.4 Bayer AG Nuclear Medicine Imaging Agents Product Portfolio
8.13.5 Bayer AG Recent Developments
8.14 Abx Advanced Biochemical
8.14.1 Abx Advanced Biochemical Comapny Information
8.14.2 Abx Advanced Biochemical Business Overview
8.14.3 Abx Advanced Biochemical Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2020-2025)
8.14.4 Abx Advanced Biochemical Nuclear Medicine Imaging Agents Product Portfolio
8.14.5 Abx Advanced Biochemical Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Nuclear Medicine Imaging Agents Value Chain Analysis
9.1.1 Nuclear Medicine Imaging Agents Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Nuclear Medicine Imaging Agents Sales Mode & Process
9.2 Nuclear Medicine Imaging Agents Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Nuclear Medicine Imaging Agents Distributors
9.2.3 Nuclear Medicine Imaging Agents Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings